Research
Hormonal
Orforglipron 45 mg significantly reduces BMI, body weight, waist circumference, and HbA1c in patients with T2DM or obesity, with efficacy increasing at higher doses.
If you have T2DM or obesity, the 45 mg dose of oral orforglipron is highly effective for reducing weight and blood sugar. It works by mimicking a gut hormone to control appetite and insulin. Expect significant results, but be aware of potential side effects like nausea.
GoodSupportsHIGH confidence
Five RCTs involving multiple orforglipron doses (3-45 mg) demonstrated that higher doses, particularly 45 mg, significantly reduced BMI (MD = -3.52 kg/m²), body weight (MD = -9.34%), waist circumference (MD = -7.19 cm), HbA1c (MD = -1.33%)... compared to placebo.
Why this rating
Network meta-analysis of 5 RCTs, though some studies had 'some concerns' about bias.
Source
Comparative Efficacy and Safety of Different Orforglipron Doses in Patients With Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Network Meta-Analysis
Marwan Tantoush et al. · Cureus · 2026
DOI 10.7759/cureus.102018
Meta-analysis · 5 studiesCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Higher doses of orforglipron (36-45 mg) are associated with increased treatment discontinuation due to adverse events compared to lower doses and placebo.Good
- Orforglipron 36 mg is the optimal dose for improving lipid profiles (triglycerides, total cholesterol) and blood pressure while maintaining better tolerability than 45 mg.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →